Objectives: The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design.
G
reat advances have been made in the treatment of schizophrenia since chlorpromazine and other typical antipsychotics were introduced in the 1950s. Many of these typical antipsychotics exhibit antipsychotic effects, especially in the positive symptoms, with the blockade of D 2 receptors being postulated as the mechanism underlying this effect. 1, 2 However, these typical antipsychotics are not very efficacious against the negative symptoms, such as blunted affect and social withdrawal, and the extrapyramidal and endocrine adverse effects they create are on clinical concern. To overcome these problems, newer antipsychotics known as atypical antipsychotics have been developed. Atypical antipsychotics are characterized by a potent serotonin-2 receptor-blocking action in addition to D 2 antagonistic action. Atypical antipsychotic drugs are generally viewed as having an efficacy approximately equivalent to that of older antipsychotics, however, with a lower risk of extrapyramidal symptoms (EPS), impaired cognition, and dysphoria commonly observed with older drugs. 3, 4 Despite this, they have been shown to potentially cause serious or significant adverse events (AEs), including body weight gain, glucose tolerance abnormalities, and hyperlipidemia. Therefore, an atypical antipsychotic with a better safety profile suitable for short-term and long-term management of patients with schizophrenia has been long sought out. 3, 4 In the earlier nonclinical studies, blonanserin (2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta [b]pyridine) has been found to have D 2 receptorYblocking activity comparable to that of haloperidol as well as potent serotonin-2 receptor-blocking activity and weak D 1 and > 1 receptor-blocking activities while being almost devoid of histamine H 1 and muscarinic M 1 antagonist activity. 5, 6 Blonanserin displaced in vitro [ 3 H]spiperone binding to rat striatal membranes and suppressed dopamine D 2 receptorYmediated behavior such as exploratory activity in mice, conditioned avoidance responses in mice and rats, and hostile responses in monkeys. 5, 6 Blonanserin also antagonized behavioral changes induced by dopaminergic overstimulation such as methamphetamine-induced hyperactivity in mice and rats and apomorphine-induced gnawing in rats and vomiting in dogs. 5, 6 Blonanserin attenuated the sensitization to phencyclidine (PCP)-induced hyperlocomotion. Further, blonanserin also attenuated the PCP-induced enhancement of immobility, and the effect of blonanserin was antagonized by a serotonin-2 receptor agonist. The antagonistic activity against the serotonin serotonin-2 receptor is possibly involved in the alleviation of the negative symptoms. 1 These findings suggest that blonanserin would be clinically effective in alleviating both the positive and the negative symptoms of schizophrenia. Clinical research on blonanserin was initiated on the basis of the above pharmacological profile of blonanserin. Clinical trials have demonstrated that blonanserin is effective in the treatment of both positive and negative symptoms of schizophrenia. Its efficacy was first demonstrated in 2 open-label, dose-ranging trials 7, 8 and was later confirmed in a double-blind comparison with haloperidol. 9 Moreover, a multicenter, randomized, doubleblind, risperidone-compared study of 302 patients with schizophrenia demonstrated its efficacy and tolerability in Japan. 10 The primary objective of this study was to evaluate the efficacy and safety of blonanserin for the treatment of Korean patients with schizophrenia using a randomized, double-blind, risperidone-compared approach.
METHODS
This study involved 15 investigative sites in Korea and was conducted from January 2006 to December 2008 in accordance with Good Clinical Practices and the International Conference on Harmonization guidelines. The study protocol received previous approval by the institutional review boards of each institution, and all patients provided written informed consent before participation.
Patients
Patients aged 18 to 65 years with a diagnosis of schizophrenia according to the Diagnostic Criteria for Research accompanying the International Statistical Classification of Diseases and Related Health Problems, 10th Revision for Mental and Behavioral Disorders, were eligible. To include a wide range of patients, both inpatients and outpatients were included in the study. Patients were required to have a Positive and Negative Syndrome Scale (PANSS) 11 score between 60 and 120 at the time of screening and baseline. Patients were excluded if they had a current Axis I disorder other than schizophrenia, a history of alcohol or drug abuse, or deteriorating/ intractable symptoms. Also excluded were the following: patients who posed a serious suicidal risk and self-injurious behaviors; those who had a history of receiving risperidone at a daily dose of 6 mg or higher before initiation of the study treatment and were determined not to have responded to treatment with administration up to 6 mg; patients who received depot antipsychotics within the 28-day period preceding baseline evaluation; patients with a history of clinically significant physical disease; women who might be or wished to become pregnant and breast-feeding mothers; or patients who, in the investigator's opinion, were otherwise ineligible to participate in the study. Demographic and disease-related data were recorded for each subject.
Study Design
This study was a randomized, double-blind, activecontrolled, multicenter, 8-week trial. During the screening period, patients were evaluated on the basis of the inclusion and exclusion criteria. Subsequently, eligible patients were randomly assigned to receive either blonanserin and risperidoneplacebo or risperidone and blonanserin-placebo in a 1:1 ratio. The drug was orally administered twice daily for 8 weeks.
Neither an observation nor a washout period was included in the study. Subjects received an initial dose of blonanserin 8 mg/d or risperidone 2 mg/d. If necessary, the dosage of blonanserin or risperidone was adjusted using the dose titration method to between 8 and 24 mg/d or between 2 and 6 mg/d, respectively. If AEs occurred, the dose of the investigational drug could be reduced. Using the results from nonclinical studies 5, 6 and the haloperidol-controlled clinical study, 12, 13 the ratio of the clinical dose of blonanserin to that of risperidone at equivalent strength was estimated to be 4 (=blonanserin/risperidone).
Efficacy Measures
All efficacy assessments were made by trained, qualified raters. Psychiatric symptoms were assessed according to the Korean version of the PANSS 11 at baseline; at weeks 2, 4, and 8; or at the time of early study termination. The mean change in the PANSS total scores from baseline to week 8 or at the end of treatment was selected as the primary variable to evaluate objectively the efficacy of the study treatment. Psychiatric symptoms were also assessed according to the 18-item Korean version of the Brief Psychiatric Rating Scale (BPRS) 14, 15 at baseline, at weeks 1, 2, 3, 4, 6, 8, or at the time of early study termination. The clusters of the BPRS are shown as follows: anxiety/depression = somatic concern, anxiety, guilt feelings, and depressive mood; angergia = emotional withdrawal, motor retardation, blunted affect, and disorientation; thought disorder = conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content; excitement = tension, mannerisms and unusual posturing, and excitement; and hostility/suspiciousness = hostility, suspiciousness, and uncooperativeness. Clinical Global ImpressionsV Improvement (CGI-I) scores 16 was assessed at baseline and week 8. Each assessment was completed by trained interraterreliable investigators in the each investigative hospital.
Safety and Tolerability
Safety assessments included monitoring of vital signs, a physical examination, clinical laboratory tests, an electrocardiogram (ECG), and AEs. To identify symptoms and signs, patient reports, investigator interviews, and physical examinations were performed at each evaluation time. Laboratory tests were performed at baseline; at weeks 2, 4, and 8; or at the time of early study termination. Given that the occurrence of extrapyramidal AEs is the main clinical issue in the treatment with antipsychotics, antipsychotic-induced AEs were assessed at baseline; at weeks 1, 2, 3, 4, 6, and 8; or at the time of early study termination according to the Drug-Induced Extrapyramidal Symptom Scale (DIEPSS-K). 17 The DIEPSS-K is a 5-point rating scale (È0Y4) for antipsychotic-induced extrapyramidal symptoms including gait, bradykinesia, salivation, muscle rigidity, tremor, akathisia, dystonia, and dyskinesia.
Statistical Analysis
The primary hypothesis was to test the noninferiority of blonanserin to risperidone treatment in patients with schizophrenia. We estimated that approximately 78 patients per group (considering dropout rate) would provide 80% power to demonstrate noninferiority of blonanserin to risperidone treatment, in primary efficacy end point, that is, PANSS total scores, in a one-sided test at the 5% significance level.
The full analysis set (FAS) was used in the primary efficacy analysis. The per-protocol set was used in an additional analysis to verify the accuracy of the results from the primary analysis. The FAS was defined as all randomized subjects, excluding the following: (a) subjects without the target disease, (b) subjects receiving no investigational drug, (c) subjects with no data after initiation of the study treatment, and (d) subjects with any violations of good clinical practice. The per-protocol set was defined as the FAS, excluding the following subjects: (a) subjects who did not meet all the inclusion criteria, (b) subjects who met any of the exclusion criteria, (c) subjects with 50% use rate or less of the investigational drugs, (d) subjects with any protocol violations/deviations during the study, and (e) subjects who received the investigational drug for fewer than 7 days.
In the efficacy analysis, a 1-sided 95% confidence interval (CI) was calculated for the difference in change in PANSS total scores between the 2 treatment groups. If the lower limit of the 95% CI was not less than j7.66, the noninferiority of blonanserin to risperidone was verified. The PANSS scores were determined by treatment group for each evaluation time point and were plotted against time. In addition, the changes in the scores by symptom and subscale were calculated by treatment group for each evaluation time point. Intergroup comparisons of the differences between baseline and postbaseline scores were made using the Wilcoxon rank sum test for each evaluation time point. Intragroup comparisons were performed with the Wilcoxon signed-rank test by treatment group for each evaluation time point. Brief Psychiatric Rating Scale and CGI-I scores were determined similarly. A 2-sided 95% CI was determined for the difference in the percentage of patients with moderate or higher improvement ratings.
The number and incidence (%) of patients with AEs were analyzed using Fisher exact test between the 2 treatment groups. Statistics for the maximum change in DIEPSS total scores were determined by treatment group and were compared by independent t test. Intergroup and intragroup comparisons were performed appropriately. In addition, the incidence of abnormal changes was calculated by treatment group and parameter. Statistics for ECG parameters (RR, QTc, PR, and QRS intervals) and QTc were determined by treatment group for each evaluation time point.
RESULTS

Patient Characteristics
Of 212 patients screened, 206 were randomly assigned to a double-blind treatment with blonanserin (n = 103) or risperidone (n = 103). One hundred eighty-three subjects (92 blonanserintreated patients vs 91 risperidone-treated patients) received the assigned investigational drugs and efficacy evaluations. Subjects who completed the 8-week treatment included 62 subjects (60.2%) for the blonanserin group and 74 subjects (71.8%) for the risperidone group (P = 0.0775). Of those who began, 39.8% of the blonanserin group and 28.2% of the risperidone group discontinued the study prematurely ( Fig. 1) . At baseline, characteristics of the 2 treatment groups were similar, and these are presented in Table 1 . Overall, the mean age was 35.21 years, and approximately 50% of patients were males. The most prominent schizophrenia subtype for all groups was paranoid schizophrenia (61.5%). During the study course, the mean duration of treatment was 45.72 T 17.96 days in the blonanserin group and 50.23 T 15.16 days in the risperidone group. The mean dosages at the final evaluation time point were 16.17 T 6.10 mg/d in the blonanserin group and 4.09 T 1.56 mg/d in the risperidone group. Of the concomitant medication, the use of anti-Parkinson medications differed between the 2 groups with 57.61% usage in the blonanserin group and 40.66% usage in the risperidone group (P = 0.0218). Finally, 23.91% of the blonanserin group 
Efficacy
The mean change from baseline to week 8 in the PANSS total scores, the primary variable, was similar with j23.48 T 19.73 for the blonanserin group and j25.40 T 18.38 for the risperidone group (Table 2) . The difference between the 2 groups was 1.92 T 19.02, and the corresponding one-sided 95% CI was j3.41. That is, the lower limit of the 95% CI, j3.41, was not less than j7.66, and the noninferiority of blonanserin to risperidone was verified.
From week 2 onward, the mean change in PANSS total scores was significantly decreased compared with baseline for both treatment groups (P G 0.001). However, the decrease in PANSS total scores did not differ between the 2 treatment groups at any evaluation time point (P = 0.1952, P = 0.1436, and P = 0.3014 at weeks 2, 4, and 8, respectively). When the PANSS subscale scores were analyzed separately, the subscale scores were also decreased at all time points after week 2 compared with baseline for both treatment groups. Moreover, the subscale scores did not differ between the 2 treatment groups at any evaluation time points. Figure 2 presents the time course of the change in PANSS total and subscale scores. Similar results were obtained using the BPRS. Mean changes from baseline to week 8 in the BPRS total scores were similar with j14.57 T 11.60 in the blonanserin group and j15.84 T 11.79 in the risperidone group. Both treatments had significant reductions in BPRS total score and scores by cluster compared with the baseline scores at every time points from week 1 onward (P G 0.0001). The decreases in BPRS total and cluster scores did not differ between the 2 treatment groups at any evaluation time point except the anergia cluster at week 8 (P = 0.0414).
The mean change from baseline to week 8 on the CGI-I showed improvement in both treatment groups with similar rates (P = 0.2530), with an improvement rate (percentage of subjects with moderate or higher improvement rating) in the blonanserin group of 51.52% and a rate of 65.33% in the risperidone group (with an intergroup difference of 13.81%; 2-sided 95% CI, 0.24%Y27.38%).
Tolerability and Safety
Adverse events were reported in 83.87% of the blonanserin group and in 85.87% of the risperidone group during the study period, and the incidences were similar in both groups (P = 0.8379). Discontinuation for reason of AEs occurred in 4 subjects from the blonanserin group and in 5 from the risperidone group. Treatment-emergent AEs that occurred in at least 5% of patients in any treatment group are summarized in Table 3 . The most frequently reported AEs among patients in the blonanserin group were akathisia (35.48%), hand tremor (32.26%), and muscle rigidity (24.73%). In the risperidone group, akathisia (22.83%), muscle rigidity (19.57%), and hyperprolactinemia (14.13%) were frequently observed. Adverse events with that occurred less frequently in the blonanserin group than in the risperidone group included dysarthria (P = 0.0288), dizziness (P = 0.0139), and increased alanine aminotransferase, aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and blood prolactin level (P = 0.0012). On the other hand, the incidences of hand tremor were higher in the blonanserin than in the risperidone group (P = 0.0006).
Of the AEs, hyperprolactinemia was higher in the risperidone group, although there was no statistical significance (P = 0.0504). Moreover, the incidences of increased prolactin were significantly higher in the risperidone group than in the blonanserin group (P G 0.05). Blood prolactin level was changed from 36.48 T 44.31 ng/mL at baseline to 43.46 T 59.76 ng/mL at the final evaluation time point in the blonanserin group. On the other hand, the change in the risperidone group was 35.60 T 43.70 ng/mL at baseline to 75.92 T 58.52 ng/mL at the final evaluation time point (Fig. 3) .
Mean change in body weight from baseline to 8 week was 1.29 T 3.48 kg in the blonanserin group (P = 0.0022) and 1.83 T 3.38 kg in the risperidone group (P G 0.0001). The risperidone group also showed the significant changes in body weight at 2 and 4 weeks compared with baseline weights (P = 0.0009 and P = 0.0002, respectively).
There was no evidence of differences in any of the following safety observations in either group: vital signs including orthostatic hypotension or pulse rate, clinically significant changes in laboratory values such as blood glucoseYrelated parameters (blood glucose, hemoglobin A1c, and insulin levels), QTc prolongation hematology, and urinalysis.
The maximum change in DIEPSS total scores between the baseline and maximum DIEPSS total score was 1.55 T 2.67 in the blonanserin group and 1.18 T 2.17 in the risperidone group (P = 0.2951). There were no significant differences in the changes from baseline in the DIEPSS score by symptom at each evaluation time point between the 2 treatment groups except for tremor. Eight subjects from the blonanserin group displayed a DIEPSS score of 1; however, no subject from the risperidone group showed a similar increase (P = 0.0432). In an intragroup comparison, a significant difference was noted in the change in DIEPSS total scores at weeks 2, 3, and 4 in the blonanserin group and at weeks 1, 2, 3, 4, and 6 in the risperidone group. Moreover, the scores of akathisia and overall severity were significantly increased. Increases in akathisia (after 2, 3, 4, and 6 weeks) and overall severity (after 3 and 4 weeks) were observed in the blonanserin group, and increases in akathisia 
DISCUSSION
The study results suggest that the efficacy and tolerability of the blonanserin were comparable to risperidone in a randomized, double-blind, risperidone-compared study for the Korean patients with schizophrenia. Statistically significant improvements in PANSS, BPRS, and CGI-I scores were observed with blonanserin, comparable to risperidone at earlier time points during an 8-week treatment period in patients with schizophrenia. In addition, blonanserin was less likely to induce the AEs often associated with antipsychotic drugs, such as increases in blood prolactin level or body weight. As with risperidone, blonanserin had little effect on blood glucoseYrelated parameters or QTc intervals.
Blonanserin displays a positive atypical index, equal to that of sulpiride. 18 The antipsychotic effects of blonanserin were evaluated using 2 animal models of PCP-induced schizophrenia and compared with those of haloperidol. 1 These findings suggest that blonanserin would be clinically effective in alleviating both the positive and negative symptoms of schizophrenia. Moreover, the double-blind trial to investigate the efficacy and tolerability of blonanserin was conducted at 37 sites in the United States, Bulgaria, the Czech Republic, and Russia. 12 Most of the study population (93.2%) was white. Our results and Garcia's were similar with the outcome of blonanserin in Japan, 10 and these demonstrate the usefulness of blonanserin in the treatment of patients with schizophrenia in a non-Japanese population.
In this study, PANSS total scores and scores by subscale were decreased after baseline compared with the scores of baseline in both treatment groups. Moreover, there were no significant differences in these scores between 2 treatment groups, irrespective of the symptom or the evaluation time point. The changes in PANSS scores in the present study were comparable to those in the haloperidol-controlled and recent risperidonecontrolled study. 9, 12 In addition, the mean daily dosage of blonanserin used in this study (14.10 T 5.17 mg/d) was similar to the haloperidol-controlled study (13.7 T 4.1 mg/d). 9 In addition, the BPRS total scores and scores by BPRS cluster showed similar results with previous studies. 10, 12 The improvement rate, as evaluated by the final global improvement rating, was similar in both treatment groups, a finding that corresponded well to that of a Japan study (51.0% and 56.5%). The improvement rates of other atypical antipsychotics (olanzapine and quetiapine) in the haloperidol-controlled clinical studies were 36% to 44%. 12 Together, these results confirm that the efficacy of blonanserin for the clinical treatment of schizophrenia was comparable to that of risperidone or haloperidol.
In this study, blonanserin was found to be safe and generally well tolerated. There was a trend for greater completer rates for risperidone group as compared to blonanserin group in our results. Approximately 39.8% of the blonanserin group and 28.2% of the risperidone group discontinued treatment. These discontinuation rate was similar with those of other trial with atypical antipsychotic (37% of the ziprasidone and 29% of the risperidone group), 19 although completion rates were low with 48 to 58% in some studies. 20, 21 The withdrawal/dropout rates in controlled trials of atypical antipsychotics in patients with schizophrenia have been approximately 19% to 34% in a metaanalysis, 22 which is nearly consistent with the values in this study. Moreover, the incidences of AEs were similar for both treatment groups (83.87% in the blonanserin group and 85.87% in the risperidone group).
On the observation of EPS symptoms, only tremor was more frequent in the blonanserin group than the risperidone group with statistical significance. In the comprehensive evaluation for EPS with the DIEPSS scale, there were no significant differences in the changes of scores by symptom at each evaluation time point between the 2 treatment groups except for tremor. The frequency of EPS-related AEs and the use of anticholinergics were similar with those of previous trials. 19, 20 Hand tremor occurred during the first or second week of treatment in the blonanserin group and tended to diminish with ongoing treatment generally. Moreover, tremor was tolerable and controlled with medication. In addition, in a recent haloperidolcontrolled clinical study, the incidence of extrapyramidal adverse effects was significantly lower in the 10-mg blonanserin group (26.6%) than in the 10-mg haloperidol group (53.3%), verifying that blonanserin is associated with a lower incidence of extrapyramidal adverse effects than that of haloperidol. 12 In this study, AEs occurring less frequently in the blonanserin group than in the risperidone group included dysarthria, dizziness, changes in liver enzyme, and increases in blood prolactin. In a Japanese study, AEs occurring less frequently in the blonanserin group included hyperprolactinemia, an increased in blood prolactin, increased appetite, and orthostatic hypotension. However, the incidences of akathisia and excitability were higher in the blonanserin group. 9, 10 Of the AEs occurring in this study, increases in blood prolactin levels and weight change may have clinical significance with respect to the usage of antipsychotics. The lower incidence of increased blood prolactin, which can lead to amenorrhea, galactorrhea, and sexual dysfunction, in the blonanserin group suggests that blonanserin has the potential merit of having a weak ability to increase blood prolactin levels, and therefore, blonanserin seems to be useful for women patients with schizophrenia. In addition, mean body weight changes tended to be lower in the blonanserin group than in the risperidone group, and the risperidone group showed a significant body weight change at an earlier time (week 2). This was parallel with previous studies of blonanserin. In a previous Japanese study, the incidence of weight increased was lower in blonanserin group than in the risperidone group (5.4% vs 10.4%, P = 0.059), and weight was only slightly increased (0.08Y0.57 kg) with no clinical significance. 12 These suggest that blonanserin is associated with a lower likelihood of the occurrence of antipsychotic-induced AEs, such as increased blood prolactin and body weight gain.
Because of the risk of ketoacidosis due to immediate increases in blood glucose, olanzapine and quetiapine should be administered carefully in the patients with a history of diabetes. 23, 24 In this study, there were no abnormal changes in the blood glucoseYrelated parameters, and no significant difference was noted in the changes in these parameters from baseline to each evaluation points for both treatment groups. About the effect of drugs on the heart, which has become a focus of discussion because of the antipsychotic-induced incidence of torsade de pointes, 25 the time course of changes in ECG parameters indicated no clinically significant change in either treatment groups and determined the risk of an effect on the heart to be slight.
Schizophrenia continues to be difficult to manage because of the complexity of the symptoms, the resistance to treatment in some refractory patients, and the poor compliance rates during longer periods because of medication-induced AEs. 12 In this trial, antipsychotic efficacy in patients with schizophrenia who took blonanserin was comparable with that of risperidone but with a better safety profile. Therefore, blonanserin may be useful in the management of schizophrenia in this respect because it has been shown to be well tolerated and effective. 12 This was an 8-week treatment study of blonanserin versus risperidone; therefore, clinical trials of longer duration are required to confirm the long-term efficacy and tolerability of blonanserin.
